![](https://endpts.com/wp-content/uploads/2024/03/Mark-McKenna-Mirador-CEO.jpg)
Mark McKenna, Mirador Therapeutics CEO
Former Prometheus execs raise $400M for precision immunology startup: 'The band is back together'
After selling his last company to Merck for $10.8 billion in June, Mark McKenna couldn’t shake the feeling that he’d left the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.